Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 83Squamous Cell Carcinoma of Head and Neck 51Carcinoma, Non-Small-Cell Lung 30Head and Neck Neoplasms 29Colonic Neoplasms 22Neoplasm Metastasis 18Neoplasms 16Rectal Neoplasms 14Pancreatic Neoplasms 10Lung Neoplasms 10Mouth Neoplasms 8Carcinoma, Squamous Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Oropharyngeal Neoplasms 6Carcinoma 6Solid Tumors 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Gastrointestinal Neoplasms 5Breast Neoplasms 5Tongue Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Thyroid Neoplasms 3Recurrence 3Melanoma 3Digestive System Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3

Interventions

trastuzumab deruxtecan 1toripalimab 1pertuzumab 1pembrolizumab 1fludarabine 1atezolizumab 1Trastuzumab 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Capecitabine 1Bronchoscopes 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Cancer × Cetuximab × 1 year × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡